Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735533) titled 'A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies' on July 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Umoja Biopharma
Condition:
Lymphoma, B Cell
Lymphoma Non-Hodgkin
High Grade B Cell Lymphoma
Richter Transformation Lymphoma
Grade 3b Follicular Lymphoma
Primary Mediastinal B Cell Lymphoma
Diffuse Large B Cell Lymphoma (DLBCL)
Intervention:
Genetic: UB-VV400
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollme...